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Monkeys mutant for PKD1 recapitulate human
autosomal dominant polycystic kidney disease
Tomoyuki Tsukiyama 1,2,10*, Kenichi Kobayashi1,3,10, Masataka Nakaya1,2,10, Chizuru Iwatani1, Yasunari Seita1,
Hideaki Tsuchiya1, Jun Matsushita1, Kahoru Kitajima1, Ikuo Kawamoto1, Takahiro Nakagawa1, Koji Fukuda4,
Teppei Iwakiri4, Hiroyuki Izumi4, Iori Itagaki1,5, Shinji Kume6, Hiroshi Maegawa6, Ryuichi Nishinakamura7,
Saori Nishio8, Shinichiro Nakamura1, Akihiro Kawauchi3 & Masatsugu Ema 1,2,9*
Autosomal dominant polycystic kidney disease (ADPKD) caused by PKD1 mutations is one of
the most common hereditary disorders. However, the key pathological processes underlying
cyst development and exacerbation in pre-symptomatic stages remain unknown, because
rodent models do not recapitulate critical disease phenotypes, including disease onset in
heterozygotes. Here, using CRISPR/Cas9, we generate ADPKD models with PKD1 mutations
in cynomolgus monkeys. As in humans and mice, near-complete PKD1 depletion induces
severe cyst formation mainly in collecting ducts. Importantly, unlike in mice, PKD1 hetero-
zygote monkeys exhibit cyst formation perinatally in distal tubules, possibly reﬂecting the
initial pathology in humans. Many monkeys in these models survive after cyst formation, and
cysts progress with age. Furthermore, we succeed in generating selective heterozygous
mutations using allele-speciﬁc targeting. We propose that our models elucidate the onset and
progression of ADPKD, which will serve as a critical basis for establishing new therapeutic
strategies, including drug treatments.
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Autosomal dominant polycystic kidney disease (ADPKD) isone of the most common hereditary diseases, with anincidence at birth estimated to be 1 in 400 to 1 in 1000
(refs. 1–3), and is 10, 15, and 20 times more common than sickle
cell disease, cystic ﬁbrosis, and Huntington’s disease, respec-
tively4. It is estimated that there are six million patients with
ADPKD worldwide, more than half of whom develop end-stage
renal disease and require dialysis or kidney transplantation by age
60 (ref. 5). Although numerous important ﬁndings have been
reported and many treatments have been proposed for ADPKD
based on studies using animal disease models and tissue culture
models6–11, and in fact some drugs have been used to slow
symptom progression12, no deﬁnitive therapies are currently
available.
It is reasonable to assume that physiological and genetic dif-
ferences explain why medications for ADPKD yield different
responses between small animals and humans. The pathological
recapitulation of human diseases is limited in mouse models
because there are marked differences in physiology between
humans and mice. Some diseases, such as Parkinson’s disease,
Alzheimer’s disease, AIDS, and inﬂuenza, cannot be recapitulated
in mice13. Most human ADPKD patients are PKD1 heterozygotes
with a germline mutation in one allele14,15. Manifestations of the
disease generally do not appear for decades, but a large-scale
study by Reed et al.16 showed that renal cysts developed in 46% of
420 children with a family history of ADPKD. Given that half of
children harbor the causative mutation, 92% of ADPKD children
should eventually demonstrate cyst development. Early cyst for-
mation was also observed in heterozygous pigs with induced
mutations and in cats and dogs with spontaneous mutations17–19.
By contrast, heterozygous deletion of Pkd1 in mice rarely results
in the formation of cysts until near the end of life, around 1.5
years after birth20,21. Although there are many types of mouse
ADPKD models, including Pkd1 or Pkd2 knockout (KO), con-
ditional KO, and induction of hypomorphic mutations, consistent
cyst formation requires biallelic mutations in most models22.
Additionally, other disease model animals used in polycystic
kidney disease studies, such as jck mice, pcy mice, Han:SPRD-Cy
rats, and PCK rats, have mutations in other genes such as Nek8,
Nphp3, Pkdr1, and Pkhd1, respectively. Thus, rodent models do
not precisely recapitulate the human disease state. To overcome
these limitations, we aimed to create a novel ADPKD model
animal in a species closely related to humans, the cynomolgus
monkey. Among species that have been generated via genome
editing with CRISPR/Cas9, the cynomolgus monkey is physio-
logically and genetically one of the closest species to humans23.
Here, we generate PKD1 KO or mosaic monkeys with various
degrees of cyst formation by using CRISPR/Cas9 technology, and
reveal the lineages of cyst epithelial cells. Furthermore, we gen-
erate heterozygous monkeys with conventional or allele-speciﬁc
gene targeting, which reveal the presence of cysts in the perinatal
stage, representing the earliest manifestations of the disease.
Results
PKD1 mutant monkeys with varying degrees of cystic severity.
For efﬁcient introduction of loss-of-function mutations, we
designed sgRNAs within exon 2 of PKD1 because frameshift
mutations in this region can result in the loss of a large percen-
tage of polycystin-1 (PC1), the translation product of PKD1
(ref. 24) (Fig. 1a). We then selected the most efﬁcient sgRNA
using a single-strand annealing (SSA) assay25 (Supplementary
Fig. 1a, b).
To determine the optimal experimental parameters, we injected
one of three concentrations (50, 100, or 200 ng/µl) of Cas9 mRNA
and 50 ng/µl of sgRNA into cynomolgus embryos. Overall, 207 of
423 embryos that survived after injection developed into
blastocysts. Among the 207 embryos, 71 were used for genotyping,
86 were used for embryo transfer to generate monkeys, and the
remaining 50 were frozen (Fig. 1b). A T7 endonuclease I (T7E1)
assay of blastocyst embryos collected at day 8 showed that almost
all embryos had mutations in the targeted region. The percentage
with mutations was 88.7% overall (63/71 embryos) (Fig. 1b,
Supplementary Fig. 1c–e). DNA sequencing conﬁrmed that the
embryos had indel mutations near the Cas9 cleavage site
(Supplementary Figs. 1f–2b). This efﬁciency was comparable to
or even higher than that in a previous study23. Despite such high
efﬁciency, the blastocyst development rate of the PKD1-mutated
embryos (46.7%) was comparable to that of wild-type (WT)
embryos (43.8%)26, although some developmental retardation was
observed (Supplementary Fig. 2c). A comparison of mutation rates
in each embryo at the three Cas9 mRNA concentrations showed
that the use of 200 ng/µl Cas9 mRNAs tended to induce higher
mutation rates than 50 and 100 ng/µl (Fig. 1c). However, we
decided to use 50 or 100 ng/µl Cas9 mRNAs to increase the
production of live animals, considering the embryonic lethality
observed in Pkd1-deﬁcient mice21.
Among 86 embryos that were transferred individually to
surrogate mothers (Fig. 1d, ET), 29 were implanted. The
pregnancy rate (33.7%) of mothers with implanted embryos
was comparable to that of mothers with WT embryos (8/23,
34.8%) that were transferred by single-embryo transfer at our
institute from 2016 to 2018. Subsequently, there were 7
miscarriages before embryonic day 150 and 8 stillbirths after
day 151, and 14 fetuses were delivered. Most of the aborted
monkeys died in the perinatal stage, because the gestational
period in cynomolgus monkeys is approximately 160 days (Fig. 1e,
day of death). It was difﬁcult to pinpoint the cause of death in
aborted monkeys, but at least in some monkeys, placental
abruption was considered to be primarily responsible. Placental
abruption is also often seen in WT monkeys. The live birth rate of
the PKD1-mutated fetuses (14/29 fetuses, 48.3%) was lower than
that of WT fetuses (7/8 fetuses, 87.5%), indicating developmental
defects in the PKD1-mutated fetuses during pregnancy. Four
neonates died spontaneously after birth; thus, 10 live monkeys
were obtained (Fig. 1d, e). In total, kidney samples were recovered
from 12 of 19 aborted or dead monkeys (Fig. 1e). After
genotyping by DNA sequencing, these aborted or dead animals
were divided into KO, mosaic, and heterozygous groups (Fig. 1e,
Supplementary Fig. 3). Additionally, kidneys of the animals in the
KO or mosaic group were classiﬁed by histological analysis into
three categories: (1) severe type, (2) intermediate type, and (3)
mild type (Fig. 1e, f, Supplementary Fig. 3). In some monkeys
(Mild #1, Severe #1, Severe #3), many tissues (kidney, liver,
spleen, stomach, pancreas, small intestine, colon, uterus, bladder,
ovary, adrenal glands, thymus, thyroid, heart, lung, brain,
skeletal muscle, skin, placenta, amnion, and umbilical cord) were
used for genotyping. However, we could not detect clear
variations in genotypes among tissues. Given that mutations
were induced early in development, it was appropriate to observe
mosaicism within individual tissues, not between tissues. There-
fore, in other monkeys, genomic DNA samples were collected
from the kidneys of dead animals, and from the placentas,
amnions, and umbilical cords of living monkeys to reduce
invasiveness. Severe-type kidneys showed formation of numerous
cysts, encompassing more than 30% of the specimen area, and
similar morphology to end-stage ADPKD kidneys in human
heterozygotes and a human infant with biallelic PKD1 abnorm-
alities27. Intermediate-type kidneys demonstrated moderate
cyst formation, covering 5–30% of the specimen area. Mild-
type kidneys exhibited sporadic cyst formation, encompassing
less than 5% of the specimen area, and similar morphology
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13398-6
2 NATURE COMMUNICATIONS |         (2019) 10:5517 | https://doi.org/10.1038/s41467-019-13398-6 | www.nature.com/naturecommunications
to early-stage ADPKD kidneys in human heterozygotes28,29
(Fig. 1f, Supplementary Fig. 3). In monkeys with intermediate-
type kidneys, it is noteworthy that there were several kidney
compartments in which more than 30% of the area was ﬁlled with
multiple cysts (Fig. 1f, the compartments surrounded by dotted
lines), similar to monkeys with severe-type kidneys, while cysts in
other compartments developed sporadically (Fig. 1f). This
suggests that intermediate-type kidneys may constitute a transi-
tional state between severe- and mild-type kidneys, since it had
features of both. Collectively, although the phenotype is variable,
due to mosaicism, the severity of the phenotype tended to
correlate with the mutation rate.
PKD1-KO monkeys show enlarged kidneys with numerous
cysts. Three of 15 aborted fetuses showed extreme abdominal
distension. The kidneys were greatly enlarged (Fig. 2a, Supple-
mentary Fig. 4a) and innumerable cysts were observed by ultra-
sonography and on cross-sections of bisected kidneys (Fig. 2b, c,
Supplementary Fig. 4b). Additionally, the fetuses had immature
lungs, indicating the presence of Potter’s phenotype with death
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from pulmonary hypoplasia (Fig. 2d, Supplementary Fig. 4c).
Histological analysis of the kidneys showed interstitial ﬁbrosis
and cysts with thin epithelial linings (Fig. 2e). This phenotype is
similar not only to that of Pkd1 null mice21 but also to that of a
human infant with biallelic PKD1 abnormalities27. Conﬁrming
the genotyping results (Supplementary Fig. 3a), immuno-
ﬂuorescence analysis with an anti-PC1 antibody detected virtually
no signals30, indicating near-complete depletion of the PC1
protein (Fig. 2f). Western blot analysis also showed that the
severe-type kidney did not express full-length PC1 protein
(Supplementary Fig. 4d). Immunohistochemistry analysis using
anti-Ki67 revealed proliferation of several epithelial cells in a few
small cysts, but there was no clear signal in the majority of
expanded cysts (Supplementary Fig. 4e). Furthermore, several
cysts were observed in monkeys’ liver and pancreatic ducts
(Fig. 2g, h, Supplementary Fig. 4f, g), conﬁrming that as in Pkd1
KO mice20,21, PC1 plays an important role in these organs. Taken
together, depletion of PKD1 in cynomolgus monkeys resulted in a
similar phenotype to that seen in PKD1-null humans and
mice21,27.
Mimicking the result of several “two-hit” mutations. In human
ADPKD patients with heterozygous mutations in one allele,
cysts may be formed after many decades when a second
mutation occurs in another allele2. Although this “two-hit”
hypothesis is still controversial, we reasoned that our mosaic
animals may at least partially mimic this situation. In contrast
to the near-complete depletion of PKD1, several cysts developed
sporadically in monkeys with mild-type kidneys (Fig. 3a).
Although the majority of normal-appearing renal tubules
expressed PC1 at similar levels as in a WT monkey, cells lining
the cysts did not express PC1 (Fig. 3a, b). It was unclear whe-
ther the absence of PC1-staining in cysts could be attributed to
lack of PC1 or to expansion of cysts derived from segments with
lower signal intensity (i.e., those from WT cells). However,
most of the WT cortex was PC1 positive, and no extensive PC1-
negative areas were observed; in contrast, in mosaic kidneys
there were extensive PC1-negative areas. Therefore, we judged
that the extensive PC1-negative areas were those where biallelic
defects occurred as a result of genome editing. Interestingly, a
fraction of normal-appearing renal tubules around the PC1-
negative cysts also hardly expressed PC1 (Fig. 3a, arrowheads),
suggesting that intercellular communication between WT and
PKD1-null cells may ameliorate the cyst severity of mutant
cells, or that the loss of PC1 protein is not sufﬁcient for cyst
formation and some other factor may be required, as stipulated
by the “three-hit” hypothesis31.
The lineage identities of cyst epithelial cells. To investigate the
origin of the cysts, the sections were stained with lotus tetra-
gonolobus lectin (LTL), a marker for the proximal renal tubule;
aquaporin-1 (AQP1), a marker for the proximal renal tubule and
the descending limb of Henleʼs loop; uromodulin (UMOD), a
marker for the thick ascending limb of Henleʼs loop; Na–Cl
cotransporter (NCC), a marker for the distal convoluted tubule;
aquaporin-2 (AQP2), a marker for the connecting tubule and the
collecting duct; and E-cadherin (ECAD), a marker for the region
from the ascending limb of Henleʼs loop to the collecting ducts
(Fig. 4a). An examination for autoﬂuorescence or non-speciﬁc
staining using negative control immunoglobulin resulted in no
clear signal. Additionally, we were able to separately stain each
nephron segment using AQP1, AQP2, NCC, and UMOD anti-
bodies (Supplementary Fig. 5a). In severe-type kidneys, most
cysts were AQP2 positive, while a few cysts were positive for
AQP1, NCC, or UMOD (Fig. 4b, Supplementary Fig. 5b), indi-
cating that most cysts were derived from the connecting tubule or
the collecting ducts. Importantly, the AQP2-positive cysts were
larger than the others (Fig. 4c, Supplementary Fig. 5c). Consistent
with this observation, it was reported that the ratio of AQP2- to
AQP1-positive cysts increased with cyst enlargement in human
end-stage ADPKD kidneys28, and similar results have been
reported in mouse models of ADPKD32,33.
In intermediate-type kidneys, AQP1-positive cysts developed
from various structures (Fig. 4d, Supplementary Fig. 6a). The
sizes of AQP1-positive cysts in the outer medulla were larger than
those of cysts in other areas (Fig. 4e). However, in compartments
where multiple cysts comprised more than 30% of the area
(Fig. 1f, the compartments surrounded by dotted lines), most of
these cysts were AQP2 positive, similar to those in severe-type
kidneys (Fig. 4f, Supplementary Fig. 6b), suggesting that cyst
formation in AQP2-positive segments is more severe than in
other segments.
In mild-type kidneys, the majority of cysts were AQP1 positive
and developed in the outer medulla, consistent with intermediate-
type kidneys (Fig. 4g, Supplementary Fig. 6c–e), whereas several
AQP2-positive cysts developed in the cortex and were larger in
size (Fig. 4g, h). Interestingly, the sizes of AQP1-positive cysts in
mild- and intermediate-type kidneys were comparable to those in
severe-type kidneys, whereas AQP2-positive cysts in severe-type
kidneys were much larger than those in mild- and intermediate-
type kidneys (Supplementary Fig. 6f). It was reported that cysts
derived from the proximal tubules were smaller than those from
the collecting ducts in humans with end-stage ADPKD and in
several mouse models, and that the majority of cysts in the
early stage were derived from the proximal segment in a
progressive mouse model28,32,33. Thus, these results suggest that
Fig. 1 PKD1 mutant monkeys with varying degrees of cystic severity. a A schematic diagram of the targeting site in the monkey PKD1 gene. b The numbers
of embryos injected with 50, 100, or 200 ng/µl Cas9 mRNAs and 50 ng/µl sgRNA. “Survived” indicates the number of survived embryos after injection.
We used embryos developed to blastocysts for genotyping analysis (Analyzed) or embryo transfer (ET) and the remaining embryos were frozen. c Box plot
of mutation detection rates in each mRNA-injected embryo. The top and bottom edges of boxes indicate the ﬁrst and third quartiles, respectively; the
center lines indicate the medians, and the ends of whiskers indicate the maximum and minimum values, respectively. n= 71 biologically independent
samples. d The numbers of aborted fetuses and delivered monkeys. e Categorization of genotypes of aborted embryos and delivered monkeys. Black bars
indicate the rates of frameshift mutations. Dark gray bars indicate the rates of in-frame mutations involving more than two amino acids. Light gray bars
indicate the rates of one- or two-amino-acid in-frame mutations and missense mutations. Off-white bars indicate wild-type (WT) rates. In the row labeled
“Allele,” “M” indicates the maternal allele, “P” indicates the paternal allele, and “ND” indicates that it was undetermined whether the alleles were maternal
or paternal. “Sequenced” indicates the number of sequences examined in this analysis. “Day of death” indicates the day of abortion. In cases of monkeys
that died after birth, the number before “+” indicates the delivery day and the number after “+” indicates the day of death. Green boxes indicate the
animals whose data are shown in f and Fig. 5a. f Low-power, H&E-stained images indicating severe-, intermediate-, and mild-type kidneys. The
compartments in intermediate-type kidneys that show features similar to those in severe-type kidneys are surrounded by dotted lines. “L” indicates left
kidneys and “R” indicates right kidneys. Arrowheads indicate cyst formation. Scale bar in large images, 1 mm. Scale bar in the small box, 100 µm. Source
data are provided as a Source Data ﬁle.
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AQP1-positive, proximal tubule-derived cysts may form prior to
AQP2-positive, collecting duct-derived cysts.
Furthermore, ECAD-positive and AQP1-, AQP2-, NCC-,
and UMOD-negative cysts were observed in all kidney types
(Fig. 4i), suggesting that these cysts were common in PKD1-
mutant monkeys. Because NCC is a marker for one portion of
the distal tubule, these cysts may have been derived from other
segments of the distal tubule. Collectively, cysts originated
from several nephron epithelial types, including AQP1-positive
proximal tubules, ECAD-positive distal tubules, and AQP2-
positive collecting ducts, in both monkeys with near-complete
deletion of PKD1 and mosaic monkeys, while cyst formation in
the collecting ducts was associated with cyst severity because
extensive or high-density cyst formations were detected in
AQP2-positive collecting ducts.
PKD1-mutated monkeys with numerous cysts can survive. Ten
live monkeys were followed up by ultrasonography of kidneys
and blood biochemical examination. Although no detectable cysts
were observed until 9 months after birth in the kidneys of Live #9,
which had a low mutation rate, several cysts developed at
6 months after birth in the kidneys of Live #5, which had a
mutation rate of more than 50% (Fig. 5a, Supplementary Fig. 3f).
Furthermore, 3 months after that, one new cyst developed in the
left kidney and one cyst in the right kidney enlarged (Fig. 5a, Live
#5). Interestingly, numerous cysts were already detected prior to
2 months after birth in the kidneys of Live #1, which had a high
mutation rate (Fig. 5a, Supplementary Fig. 3f). Two monkeys with
93.8% and 69.6% frameshift mutations (Live #1 and #4, respec-
tively) showed formation of numerous cysts. On the other hand,
two monkeys with 8.6% and 18.2% frameshift mutations (Live #9
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Fig. 2 PKD1-KO monkeys show enlarged kidneys with numerous cysts. a Enlarged kidneys in monkeys with severe-type kidneys. b Ultrasonography of the
kidneys. “L” indicates left kidneys and “R” indicates right kidneys. c The gross appearances and cross-sections of severe-type kidneys and WT kidneys on
the same scale. d The immature lungs of monkeys with severe-type kidneys and a WT monkey on the same scale. “Day” indicates the day of abortion.
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severe-type kidney. Asterisks indicate cysts. Scale bar, 100 µm. g Liver cysts. “Cy” indicates cysts. Scale bar, 100 µm. h A pancreatic cyst. “Cy” indicates
a cyst and “D” indicates a duct. Scale bar, 100 µm.
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and #10, respectively) showed no cyst formation. The other six
monkeys showed mild cyst formation (Supplementary Table 1),
indicating that the frequency of cyst formation tended to correlate
with the mutation rate of the PKD1 gene.
Blood tests at 6 and 12 months after birth showed no
remarkable abnormalities in any monkeys demonstrating cyst
formation (Fig. 5b), indicating that nephron compensation
occurred in monkeys as it does in humans. This result is
reasonable because it is known that in humans with progressive
renal enlargement, nephron compensation enables the glomer-
ular ﬁltration rate to remain within the normal range for several
decades, until more than 50% of the functioning parenchyma
has been destroyed5. Given that monkeys have longer life spans
than rodents, and the cyst formation in our primate models
resembled not only that in late-stage human patients but also
that in pediatric patients, we can monitor the disease state over
the long term and thereby elucidate the molecular mechanisms
of ADPKD and assessing drug efﬁcacy and toxicity.
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Heterozygotes exhibit distal-tubules-derived small cysts. Het-
erozygous animals had the WT sequence in one allele and a
mutation in the other, which is likely also the case in human
ADPKD patients (Supplementary Fig. 7a). Kidneys in hetero-
zygotes showed formation of a few cysts perinatally (Fig. 6a,
Supplementary Fig. 7b). Although most of the cysts were small,
we conﬁrmed that these cysts were rarely detected in WT mon-
keys aborted around full-term gestation (Supplementary Fig. 7c).
Notably, a clear cyst was detected by ultrasonography in a live
heterozygous monkey (Hetero #3), and this cyst was conﬁrmed
on the cut surface of the kidney (Fig. 6a). These results clearly
demonstrated the presence of cysts perinatally in heterozygous
monkeys, which is similar to the situation in heterozygous
humans but not mice16,20,34.
While small numbers of cysts in the heterozygotes were AQP2
positive, most were ECAD positive but negative for the other
markers (Fig. 6b, c, Supplementary Fig. 7d). This type of cyst also
formed in monkeys with near-complete deletion of PKD1 and in
mosaics, as described above (Fig. 4i). Thus, this cyst type may
precede the formation of AQP1- or AQP2-positive cysts and may
represent the earliest manifestation of the disease, although long-
term monitoring is required for deﬁnite proof. Most cysts in
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heterozygotes were PC1 negative, consistent with the “two-hit”
hypothesis (Fig. 6d, Hetero #1). The formation of multiple PC1-
negative cysts in early age is surprising because it is thought that
multiple cyst formation results from the accumulation of second
mutations with age. Interestingly, several PC1-positive cysts were
also observed (Fig. 6d, Hetero #3). We examined the presence of
autoﬂuorescence or non-speciﬁc staining using negative control
immunoglobulin at the same concentration as anti-PC1 antibody
(20 μg/ml) and detected no clear signal (Supplementary Fig. 7e).
This suggests that these cysts may be caused by PKD1
haploinsufﬁciency, although there is a possibility that the signal
was non-speciﬁc because some extra bands were detected in
western blotting (Supplementary Fig. 4d). Consistent with this
observation, it was reported that some cysts were PC1 positive in
humans35,36. These results are in sharp contrast to those in mice,
where efﬁcient cyst formation was shown to require biallelic
mutations22.
In humans, therapies for ADPKD are limited; thus, active
therapeutic intervention is not recommended in pediatric patients
with no remarkable symptoms37. Consequently, in ADPKD
patients the pathological process from the presymptomatic stage
to the early stage remains a black box. Understanding how cysts
develop and worsen in the early stage in heterozygotes may be
useful in designing drugs to prevent cysts from enlarging.
Generation of heterozygotes by allele-speciﬁc targeting. Using
the conventional method to target exon 2, we were able to obtain
ﬁve heterozygotes, including two animals from which kidney
samples were not collected, but the efﬁciency was low (5 of 29
monkeys; Supplementary Table 1). Since Ma et al.38 succeeded in
correcting a speciﬁc pathogenic allele in human embryos at high
efﬁciency, we attempted to target a single allele using allele-
speciﬁc polymorphisms. We searched for polymorphisms in the
monkey PKD1-coding region and found that a region of exon 4
had a single-nucleotide polymorphism. Oocytes and sperm from
monkeys bred in different countries (China and Indonesia) were
used to generate embryos with this polymorphism in the
maternal allele. In these embryos, a guide RNA (gRNA) targeting
the region was unable to recognize the maternal allele, but could
speciﬁcally recognize the paternal allele; thus, mutations were
induced only in the paternal allele (Fig. 7a). To reduce the off-
target effect in this experiment, instead of injecting mRNA 6 h
after intracytoplasmic sperm injection (ICSI), we co-injected a
gRNA/Cas9 protein RNP complex with sperm or electroporated
the RNP complex into embryos immediately after ICSI38,39. In an
in vitro experiment using a low concentration (20 ng/µl) of Cas9
protein, incomplete mutagenesis and mosaicism were observed
(Supplementary Fig. 8a). Therefore, we decided to use a high
concentration (200 ng/µl) of Cas9 protein to completely introduce
mutations into single-cell embryos and thus avoid mosaicism.
Two fetuses (Ex4 Severe #1 and Ex4 Hetero #1) were aborted
spontaneously and two live monkeys (Ex4 Live #1 and Ex4 Live
#2) were obtained. One aborted fetus (Ex4 Severe #1) had
frameshift mutations in both alleles and showed a similar
phenotype to monkeys with PKD1 depletion (Supplementary
Fig. 8b–g), clearly demonstrating that the phenotype was caused
by mutations in PKD1 and not by gRNA off-target effects,
because two different gRNAs were able to induce a similar
phenotype. DNA sequencing showed that the other three
monkeys were heterozygotes (Supplementary Fig. 8h, i). To date,
eight monkeys have additionally been generated and 10 of 12
monkeys have been shown to be heterozygotes or monoallelically
affected. Moreover, among these 10 monkeys, nine have a single
mutation, and therefore only 3 of 12 monkeys demonstrate
mosaicism. This is quite different from exon 2 targeting, where
most animals exhibit mosaicism, illustrating a dramatic improve-
ment in our ability to generate non-mosaic heterozygotes
(Supplementary Table 1). Histological analysis detected small
cysts in the kidneys of the aborted fetus (Ex4 Hetero #1) (Fig. 7b),
and the cysts were ECAD positive and AQP1, AQP2, NCC, and
UMOD negative (Fig. 7c, d). These results were similar to those in
exon 2 heterozygotes, indicating the shared biological character-
istics of exon 2 and exon 4 heterozygotes. Overall, most of the
cysts in the heterozygotes were ECAD positive, while some cysts
were also positive for AQP2 and were larger than the others
(Fig. 7e). Furthermore, the kidneys in the two living monkeys
(Ex4 Live #1 and Ex4 Live #2) were followed up by
ultrasonography, and formation of a few cysts was detected at
birth or by 2 months after birth, respectively (Fig. 7f, g). These
cysts had enlarged at 6 months after birth (Fig. 7g, right images).
Because some kidney cysts were identiﬁed in human hetero-
zygous children16,34, we propose that the heterozygous monkeys
in this study may serve as a useful model for the study of human
ADPKD, including pediatric patients.
Generation of a ﬂoxed allele in monkey embryos. Finally, we
applied conditional KO to PKD1 mutagenesis to verify in detail
the mechanism of cyst formation according to the “two-hit”
hypothesis. We used a long single-strand oligonucleotide (long
ssODN)40–43 with two substituted bases and three gRNAs to
efﬁciently create a ﬂoxed/indel monkey at the F0 generation
(Fig. 8a). Three of 30 embryos had a ﬂoxed allele, as determined
by restriction fragment length polymorphism (RFLP) analysis
(Fig. 8b, c) and DNA sequencing (Fig. 8d). Genomic fragments
Fig. 4 The lineage identities of cyst epithelial cells. a Schematic diagram showing nephron segments positive for each marker. “C” indicates the cortex,
“OM” indicates the outer medulla, and “IM” indicates the inner medulla. b Expressions of nephron segment markers in a severe-type kidney. Small boxes
indicate regions containing representative cysts positive for AQP1, AQP2, NCC, or UMOD, respectively; cyst areas that are positive for each marker are
surrounded by white lines. Scale bar in large images, 1 mm. Scale bar in small boxes, 100 µm. c Box plot of the areas of AQP1-, AQP2-, NCC-, or UMOD-
positive cysts in three severe-type kidneys. n= 768 cysts in three animals. d Expressions of nephron segment markers in an intermediate-type kidney.
Small boxes indicate the regions shown at high magniﬁcation in f. Cyst areas that are positive for AQP1, AQP2, or UMOD, respectively, are surrounded by
white lines. ND indicates not detected. Scale bar, 1 mm. e Box plot of the areas of AQP1-, AQP2-, NCC-, or UMOD-positive cysts in the intermediate-type
kidneys. “C” indicates the cortex, “OM” indicates the outer medulla, “IM” indicates the inner medulla. n= 1008 cysts in one animal. f Expressions of
nephron segment markers in an intermediate-type kidney compartment containing multiple cysts similar to those in severe-type kidneys. Scale bar, 1 mm.
g Expressions of nephron segment markers in mild-type kidneys. The cyst areas that are positive for AQP1 or AQP2 in the cortex, the outer medulla, or
inner medulla are surrounded by white lines. “L” indicates a left kidney and “R” indicates a right kidney. ND indicates not detected. Scale bar, 1 mm. h Box
plot of the areas of AQP1-, AQP2-, NCC-, or UMOD-positive cysts in intermediate-type kidneys. “C” indicates the cortex, “OM” indicates the outer
medulla, and “IM” indicates the inner medulla. n= 123 cysts in four animals. i Representative ECAD-positive and AQP1-, AQP2-, NCC-, and UMOD-
negative cysts. Asterisks indicate the cysts. Scale bar, 100 µm. In the box plots, the top and bottom edges of boxes indicate the ﬁrst and third quartiles,
respectively; the center lines indicate the medians; and the ends of whiskers indicate the maximum and minimum values, respectively. Source data are
provided as a Source Data ﬁle.
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containing the outer regions of homologous arms were ampli-
ﬁed by PCR (Fig. 8a, blue triangles), and the fragments were
cloned into vectors and sequenced. The sequencing analysis
conﬁrmed cis insertion of LoxP sites in all three ﬂoxed embryos
(Fig. 8d). In one embryo (Experiment 1, #4), we detected a single
LoxP insertion. Additionally, we conﬁrmed the sequence ﬁdelity
of junctional regions in two of three ﬂoxed embryos. This is the
ﬁrst successful generation of a ﬂoxed allele in nonhuman pri-
mates. Introduction of Cre recombinase into this ﬂoxed allele
would further accelerate the study of ADPKD in primates. Once
the ﬂoxed monkeys are generated, deletion of PKD1 in renal
tubule cells can be achieved by viral delivery of Cre enzyme.
Although viral delivery may cause mosaic Cre expression, we
can take advantage of the mosaicism for long-term studies.
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Discussion
In summary, we generated multiple types of PKD1 mutants in
cynomolgus monkeys. Complete or mosaic deletion led to cyst
formation with various degrees of severity, which tended to
correlate with the mutation rate. In heterozygotes, it takes a long
time for cysts to occur frequently, and therefore it will
presumably take time to start preclinical testing. On the other
hand, in a mosaic animal with partial biallelic mutation, animals
showing some degree of cyst formation can probably be obtained
at an early stage and should therefore be useful for preclinical
studies. Other large animal models, such as those involving
induced mutations in pigs and spontaneous mutations in cats and
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dogs, are also useful for preclinical testing. However, monkeys are
more similar to humans genetically and physiologically than these
animals. Additionally, like in humans, genetic diversity is higher
in monkeys than in other model animals. These features are
advantageous for preclinical studies. Certainly, it is true that the
use of monkeys would involve expensive and long-term studies.
However, although ADPKD is a very common monogenic disease
that occurs very frequently, it is also true that treatment methods
are still limited despite several decades of research thus far. Even
if it takes time and money, we believe it is time to try a new
research approach.
Heterozygous monkeys have an advantage over mouse models
in terms of determining how cysts develop and aggravate in
human heterozygotes with ADPKD. In contrast to mice, which
require conditional knockout to mimic the human phenotype, it
is feasible to investigate the process of cyst formation in a more
natural state using our monkey model. We engineered a PKD1
allele using allele-speciﬁc targeting, and for the ﬁrst time selec-
tively generated PKD1 heterozygote nonhuman primates that
formed cysts in a similar way as human pediatric patients. Since
heterozygotes without mosaicism can be prepared, we believe that
they can be studied genetically in a relatively homogeneous
population. Although this will of course take time, in the future
we can perform this research under more genetically homo-
geneous conditions in family pedigrees by analyzing the F1
generation. We have not yet evaluated the fertility of the monkeys
we generated, but given that human ADPKD patients are fertile,
we believe that these monkeys will be fertile and can generate
multiple pedigrees. The pathology in heterozygotes was similar to
that in humans, so the same pathological progression can be
a
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expected in the F1 generation. Therefore, we hope that eluci-
dating the mechanisms by which cysts develop and worsen may
identify treatment that can begin in childhood. Generally, active
therapeutic interventions in pediatric patients, including mole-
cular diagnosis, are not recommended, and research in children
of ADPKD patients is ethically difﬁcult because ADPKD shows
100% penetrance and there is no deﬁnitive therapy. In humans,
therefore, it has only been revealed that cysts have developed
since childhood, and the details are unknown. Additionally, since
rodent models do not precisely recapitulate the disease state in
humans, the pathological process from the presymptomatic
stage to the early stage in humans remains a black box. We
identiﬁed the lineage identities of cyst epithelia and found that
most cysts in heterozygotes were derived from the distal tubules,
which may reﬂect the initial stage of cystogenesis and represent
the earliest manifestations of the disease. Thus, although the
collecting ducts are the only drug target in adulthood patients,
our results suggest that the distal tubules may be a novel drug
target in pediatric patients for whom there is currently no clinical
intervention.
We also found that cyst formation in the collecting ducts was
associated with cyst severity. Although tolvaptan, a selective
vasopressin V2 receptor antagonist, is currently the most com-
mon drug used to treat ADPKD patients and effectively sup-
presses increases in kidney volume12, the outcomes and side
effects after long treatment durations are unclear, especially in
pediatric patients. Tolvaptan targets the collecting ducts because
they are the location of vasopressin V2 receptor expression. The
results in our animal model suggest that severe cysts develop in
the collecting ducts, even at a young age. Although initiation of
tolvaptan treatment beginning in the early stage of cyst formation
is expected to suppress cyst enlargement, it is unfeasible to per-
form clinical studies in pediatric patients prior to conducting
preclinical studies in an animal model. Our monkey model is
valuable in this regard as it allows for long-term drug evaluation
beginning at a young age.
It is difﬁcult to clearly demonstrate off-target sequence
alterations in a genome-wide manner due to limited genomic
information in the cynomolgus monkey. Therefore, we used two
different gRNAs to show that observed phenotypes were caused
by on-target mutations. Interestingly, compared with WT mon-
keys, we observed higher abortion rates not only with exon 2
targeting but also with exon 4 targeting. In mice, it was shown
that loss of Pkd1 caused placental defects44. Thus, we suspect that
abnormal function of PKD1 may be a cause of the high rate of
abortion.
Recently, advances in human kidney organoid research enabled
the generation of PKD1-null cyst formation in vitro45,46.
Although the organoids can directly utilize human cells to
unravel the mechanism of cyst formation, these cells are poorly
differentiated and the culture period is limited. Some monkeys in
our model survive even after the formation of numerous cysts
(Fig. 5a). Therefore, we propose that this model is useful for long-
term observation, elucidating the molecular mechanisms of
ADPKD, and assessing drug efﬁcacy and toxicity.
Methods
Study approval. We followed the Reporting in Vivo Experiments (ARRIVE)
guidelines developed by the National Centre for the Replacement, Reﬁnement &
Reduction of Animals in Research (NC3Rs). We also followed The Act on Welfare
and Management of Animals from Ministry of the Environment, Fundamental
Guidelines for Proper Conduct of Animal Experiment and Related Activities in
Academic Research Institutions under the jurisdiction of the Ministry of Educa-
tion, Culture, Sports, Science and Technology, and Guidelines for Proper Conduct
of Animal Experiments from Science Council of Japan. All animal experimental
procedures were approved by the Animal Care and Use Committee of Shiga
University of Medical Science (approval number: 2015-5-13, 2016-6-1).
Animals. For oocyte collection, female cynomolgus monkeys (Macaca fascicularis),
ranging in age from 4 to 13 years, were selected for this study. In this study,
monkeys were never sacriﬁced and only animals that died naturally were used for
sampling. The light cycle was 12 h of artiﬁcial light from 8 a.m. to 8 p.m. Each
animal was fed 20 g/kg of body weight of commercial pellet monkey chow (CMK-1;
CLEA Japan) in the morning, supplemented with 20–50 g of sweet potato in the
afternoon. Water was available ad libitum. Temperature and humidity in the
animal rooms were maintained at 25 ± 2 °C and 50 ± 5%, respectively.
Vector construction. pX330 was purchased from Addgene (Plasmid #42230)47. To
construct pX330-monPKD1, oligo-DNAs listed in Supplementary Table 2 were
annealed and ligated into the BbsI site of pX330. To construct pCAG-EGxxFP-
monPKD1, an ampliﬁed PCR product was cloned into the EcoRI–NheI sites of
pCAG-EGxxFP25. The primers for PCR are listed in Supplementary Table 2.
SSA assay. 293FT cells were simultaneously transfected with pX330-monPKD1
and pCAG-EGxxFP-monPKD125. Two days after incubation in Dulbecco’s mod-
iﬁed Eagle’s medium (Sigma) containing 10% fetal bovine serum (Sigma), the cells
were collected and analyzed with ﬂow cytometry.
mRNA in vitro transcription. To add the T7 promoter sequence to the Cas9
coding region and the sgRNA sequence, PCR ampliﬁcation was performed48. The
PCR products were treated with 0.5% SDS, 0.2 mg/ml Proteinase K for 30 min at
50 °C, puriﬁed with phenol–chloroform, and precipitated with ethanol. Then, the
puriﬁed PCR products were used as templates for in vitro transcription. The Cas9
and sgRNA mRNAs were transcribed using the mMESSAGE mMACHINE T7
Transcription Kit and the MEGAshortscript T7 Transcription Kit (Thermo Fisher
Scientiﬁc), respectively. The mRNAs were puriﬁed with the MEGAclear Tran-
scription Clean-Up Kit (Thermo Fisher Scientiﬁc). The primers for in vitro tran-
scription are listed in Supplementary Table 2.
Intracytoplasmic sperm injection. Two weeks after the subcutaneous injection of
0.9 mg of a gonadotropin-releasing hormone antagonist (Leuplin for Injection Kit;
Takeda Chemical Industries), a microinfusion pump (iPRECIO SMP-200, ALZET
Osmotic Pumps) with 15 IU/kg human follicle-stimulating hormone (hFSH,
Gonapure Injection; Asuka Pharmaceutical) was embedded subcutaneously under
anesthesia and injected 7 μl/h for 10 days49,50. After the hFSH treatment, 400 IU/kg
human chorionic gonadotropin (hCG, Gonatropin; Asuka Pharmaceutical) was
injected intramuscularly. Forty hours after the hCG treatment, oocytes were col-
lected by follicular aspiration using a laparoscope (LA-6500, Machida Endoscope).
Cumulus-oocyte complexes (COCs) were recovered in alpha modiﬁcation of
Eagle’s medium (MP Biomedicals, Solon), containing 10% serum substitute sup-
plement (Irvine Scientiﬁc). The COCs were stripped off cumulus cells with 0.5 mg/
ml hyaluronidase (Sigma Chemical). ICSI was carried out on metaphase II (MII)-
stage oocytes in mTALP containing HEPES with a micromanipulator. Fresh sperm
were collected by electric stimulation of the penis with no anesthesia.
Microinjection of mRNA into ICSI embryos. For mRNA microinjection,
pronuclear-stage embryos were prepared by 6-h culture after ICSI. Following ICSI,
embryos were cultured in CMRL Medium-1066 (Invitrogen) supplemented with
20% bovine serum (Invitrogen) at 38 °C in 5% CO2 and 5% O2. Microinjections of
mRNA were performed under microscopy with a micromanipulator. A mixture of
50, 100, or 200 ng/µl Cas9 mRNA and 50 ng/µl sgRNA were injected into the
cytoplasm of embryos after 6 h of ICSI.
T7 endonuclease I (T7E1) assay. To reduce ampliﬁcation bias, the genomic
DNAs from embryos were ampliﬁed with the REPLI-g Mini Kit (Qiagen). The
targeted sequences were ampliﬁed from the samples and puriﬁed with Wizard SV
Gel and the PCR Clean-Up System (Promega). The puriﬁed sequences were
denatured, reannealed, and digested with T7E1 (NEB) for 2 h at 37 °C. The elec-
trophoresis was performed using 2% agarose gels. To extract genomic DNAs from
tissue samples, the samples were digested in lysis buffer (10 mM Tris-HCl (pH 8.0),
100 mM NaCl, 50 mM EDTA, 0.5% SDS, and 0.5 mg/ml Proteinase K). The lysate
was treated with phenol and phenol–chloroform and precipitated with ethanol,
followed by denaturing, reannealing, and digesting with T7E1.
DNA sequencing. For DNA sequencing, the PCR products with mutations
detected by T7E1 assay were cloned into the EcoRV site of pBRBlue II. For each
sample, multiple PCR products from different tubes were cloned to reduce bias. To
determine the genotypes of fetuses and offspring, genomic DNA samples were
collected from the kidneys of dead animals, as well as from the placentas, amnions,
and umbilical cords of living monkeys. The parental origin of each sequence was
determined by polymorphism analysis.
Embryo transfer. When embryos developed to expanded blastocysts, one embryo
was transferred into each appropriate recipient female49,50. Embryos were aspirated
into a catheter (ETC3040SM5-17; Kitazato Medical Service) under a stereomicroscope.
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The catheter was inserted into the oviduct of the recipient via the ﬁmbria under the
laparoscope, and the cultured embryo was transplanted with a small amount of
medium. Pregnancy was determined by ultrasonography 30 days after ICSI.
Tissue sectioning and hematoxylin–eosin (H&E) staining. For tissue sectioning,
the samples were ﬁxed in Bouin’s solution overnight at 4 °C, washed in 70%
ethanol, and embedded in parafﬁn. The parafﬁn blocks were sectioned at a
thickness of 2–4 μm on a microtome and mounted on glass slides (Platinum Pro,
Matsunami). The parafﬁn sections were de-parafﬁnized with xylene followed by
rehydration. Each slide was stained with H&E.
Immunohistochemistry. For immunohistochemistry, the parafﬁn sections were
de-parafﬁnized with xylene followed by rehydration. Each slide was autoclaved for
20 min at 121 °C in Histoﬁne solution (Nichirei Biosciences) for antigen retrieval.
The slides were then washed with PBS and incubated in 0.3% H2O2/methanol for
30 min at room temperature to inactivate endogenous peroxidase. After washing
three times with PBS, the slides were blocked with 2% normal goat serum/PBS for
30 min at room temperature and incubated with primary antibodies in the blocking
solution for 1 h at room temperature. After washing three times with PBS, the
slides were incubated with HRP-conjugated secondary antibodies in the blocking
solution for 1 h at room temperature. After washing three times with PBS, the
slides were incubated in 0.1 mg/ml DAB/0.03% H2O2/50 mM Tris-HCl (pH 7.6)
for 3–5 min at room temperature. Finally, after hematoxylin counterstaining and
hydrophobization, the sections were mounted with mounting medium (MP500,
Matsunami).
For immunoﬂuorescence analysis, after antigen retrieval the slides were
permeabilized with 0.2% Triton-X/PBS for 30 min at room temperature. After
washing with PBS, the slides were blocked with 10% normal donkey serum/2%
skim milk/0.1% Tween-20/PBS for 1 h at 4 °C and incubated with primary
antibodies in the blocking solution overnight at 4 °C. After washing three times
with 0.1% Tween-20/PBS, the slides were incubated with Alexa 488-, 546-, 594-,
633-, or 647-conjugated secondary antibodies and Hoechst 33342 in 2% skim milk/
0.1% Tween-20/PBS for 1 h at room temperature or for 4 h at 4 °C. After washing
three times with 0.1% Tween-20/PBS, the slides were mounted with mounting
medium (Vectashield; Vector Laboratories). The antibodies used in this study were
as follows: anti-PC1 (7E12) (sc-130554, 1:10 dilution; Santa Cruz Biotechnology),
anti-Ki67 (M7240, 1:200 dilution; Dako), anti-AQP1 (ab15080, 1:500 dilution;
Abcom), anti-AQP1 (HPA019206, 1:1000 dilution; Sigma), anti-AQP2 (A7310,
1:200 dilution; Sigma), Biotinylated LTL (B-1325, 1:300 dilution; Vector), anti-E-
Cad (AF748, 1:100 dilution; R&D), anti-UMOD (HPA043420, 1:1000 dilution;
Sigma), anti-NCC (HPA028748, 1:200 dilution, Sigma), negative control mouse
IgG1 (X0931, 1:5 dilution, Dako), and negative control rabbit immunoglobulin
fraction (X0936, 1:3000 dilution, Dako).
Western blotting. For western blotting, tissues were ﬁxed by 10% trichloroacetic
acid immediately after freeze fracturing to avoid protein degradation. The ﬁxed
samples were treated with 9 M urea, 2% Triton X-100, and 1% dithiothreitol
solution to solubilize protein. After sonication, 10% lithium dodecyl sulfate solu-
tion was applied to the samples. The samples were sonicated again and were
separated by SDS-PAGE. After blotting, the membranes were blocked with 5%
skim milk/0.1% Tween-20/TBS for 1 h at room temperature and incubated with
anti-PC1 antibodies (7E12, sc-130554, 1:100 dilution, Santa Cruz Biotechnology;
E8, 8C3C10, 1:3000 dilution, Baltimore PKD Core Center; 5F4D2, MABS1252,
1:200 dilution, Millipore) in 1% skim milk/0.1% Tween-20/TBS overnight at 4 °C.
After washing three times with 0.1% Tween-20/TBS, the membranes were incu-
bated with HRP-conjugated secondary antibodies in 1% skim milk/0.1% Tween-20/
TBS for 1 h at room temperature. After washing three times with 0.1% Tween-20/
TBS, immunoreactive proteins were detected with enhanced chemiluminescence
(Cemi-Lumi One Super, Nacalai) and an ImageQuant LAS 4000 imager (GE
Healthcare). After stripping with WB Stripping Solution Strong (Nacalai), beta-
actin proteins were detected with Anti-beta-actin pAb-HRP-DirectT (PM053-
7, MBL).
Construction of the gRNA/Cas9 protein RNP complex. The crRNA, tracrRNA,
and HiFi Cas9 proteins were purchased from Integrated DNA Technologies. The
construction of the gRNA/Cas9 protein RNP complex was performed according to
the manufacturer’s instructions.
Construction of the knock-in vector and long ssODN. To construct the ﬂoxed
exon 4 knock-in vector, three ampliﬁed PCR products containing loxP sequences
were cloned into the XhoI–NotI site of pBRBlue II, then two ampliﬁed PCR pro-
ducts containing two substituted bases from the vector were cloned into the XhoI–
NotI site of pBRBlue II. An ampliﬁed PCR product from the vector was used as the
template for the long ssODN, which was produced using the Guide-it Long ssDNA
Production System (TaKaRa). The primers for PCR are listed in Supplementary
Table 2.
Co-injection of RNP complex and sperm and electroporation. MII oocytes were
collected as described above. The RNP complex was co-injected with sperm during
ICSI38. MII oocytes and sperm were washed in a drop of 200 ng/µl RNP complex in
opti-MEM (Invitrogen), and ICSI was performed in the drop. Electroporation of
the RNP complex into ICSI embryos was performed using a Super Electroporator
NEPA21 (Nepa Gene). In brief, 10 min after ICSI, zygotes were placed in the glass
chamber between 1-mm-gap platinum electrodes (Nepa Gene); this chamber was
ﬁlled with 6 µl of opti-MEM containing 200 ng/µl RNP complex39. The poring
pulse parameters were as follows: voltage, 40 V; pulse width, 3.5 ms; pulse interval,
50 ms; and number of pulses, +4. The transfer pulse parameters were as follows:
voltage, 5 V; pulse width, 50 ms; pulse interval, 50 ms; and number of pulses, ±5.
Blood analysis. In the hematological analysis, we examined leukocyte count
(WBC), erythrocyte count (RBC), hemoglobin concentration (HGB), hematocrit
value (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin
(MCH), mean corpuscular hemoglobin concentration (MCHC), and platelet count
(PLT) using ADVIA120 (Siemens Healthcare Diagnostics Manufacturing). In the
blood biochemical test, we examined aspartate transaminase (AST), alanine
transaminase (ALT), lactate dehydrogenase (LDH), total bilirubin (T-bil), total
protein (TP), albumin (ALB), globulin (Glob), albumin/globulin ratio (A/G), glu-
cose (GLU), urea nitrogen (UN), inorganic phosphorus (IP), calcium (Ca), sodium
(Na), potassium (K), chloride (Cl), beta2-microglobulin (B2m), triglycerides (TG),
total cholesterol (T-cho), creatinine (Cre), and uric acid (UA) with JCA-BM6070
(JEOL), and cystatin C (Cys C) with a human cystatin ELISA (BioVender—
Laboratorni Medicina).
Statistical analysis. One-way ANOVA and post hoc contrasts were used for the
comparisons in Figs. 1c, 4c, e, h, 7e, and Supplementary Figs. 2c, 5b, and 6f.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1c, 4c, e, h, 5b, 7e and 8b and Supplementary Figs 1c,
1d, 1e, 2c, 4d, 5c and 6f and Supplementary Table 1 are provided as a Source Data ﬁle.
The datasets generated or analyzed during the current study are available from the
corresponding author on reasonable request.
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